Form 4: ANI Pharma CFO's Tax-Related Stock Sale

ANI Pharmaceuticals' SVP & CFO, Stephen P. Carey, disposed of 5,503 shares of common stock for tax purposes related to performance stock unit vesting.

Summary

• Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals, Inc. (ANIP), reported a transaction involving the company's common stock.
• On February 11, 2026, 5,503 shares of common stock were disposed of at a price of $76.25 per share.
• This disposition was for tax purposes, exempt under Rule 16(b)-3, in connection with the vesting of 16,210 performance stock units (PSUs).
• The grant of these PSUs was previously reported on April 6, 2023.
• Following this transaction, Stephen P. Carey beneficially owns 175,360 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a mechanical tax withholding related to equity compensation vesting, rather than a discretionary sale or purchase, and thus does not reflect a change in management's sentiment towards the company's prospects.

Positives

• The underlying event, the vesting of 16,210 performance stock units, indicates that performance targets were likely met, which is a positive for the executive and potentially reflects well on company performance.

Negatives

• The disposition of 5,503 shares reduces the direct beneficial ownership of the SVP & CFO, although this is a non-discretionary sale for tax purposes.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that the disposition of shares for tax withholding purposes upon the vesting of equity awards is a common and routine practice for executives receiving equity compensation across various industries. It is a standard mechanism to cover tax liabilities arising from the income recognized upon vesting.

Comparison to Industry Standards

• Tax withholding upon the vesting of performance stock units is a standard practice in executive compensation across publicly traded companies, aligning with global benchmarks for managing equity-based income taxes.
• This type of transaction is comparable to similar tax-related sales seen at companies like Pfizer or Merck when their executives' restricted stock units or performance shares vest, where a portion of the shares are automatically sold to cover statutory tax obligations.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary tax-related transaction and not indicative of a change in the executive's confidence in the company.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares for tax withholding purposes following the vesting of performance stock units. Such transactions are common for executives receiving equity compensation and typically do not signal a change in the company's fundamentals or management's outlook. Therefore, a seasoned investor would likely maintain their current position, as this event provides no new material information to warrant a change in investment strategy.

Keywords

ANIP, Form 4, insider transaction, stock sale, tax withholding, equity compensation, Stephen P. Carey, performance stock units